Biologics in Rheumatology - JAK and TNF alpha

Speciality: Rheumatology


Speaker:

Prof ( Dr ) Ved Chaturvedi | MD, DM, Sr Consultant Rheumatology & Immunology

DR P D RATH | MD,FACR,FRCP(Edin),FRCP(Glasgow) FNIMS,FRCM,GCPR(AUS), Diploma MSK USG(UCAM SPAIN) Director & Head Of Deptt. Rheumatology

Dr. Nilesh Nolkha | MD, DM (Clinical Immunology & Rheumatology), Consultant Rheumatologist

Description:

A warm welcome to all the medical professionals in this memorable scientific session of JAKi and TNFi in rheumatological disorder.

The primary subject of discussion in this webinar is immunological responses in rheumatic diseases and the role of TNF alpha inhibitors and JAK inhibitors in rheumatological disorders. You will get a broader knowledge of the above mentioned topic through the real world evidence provided in this session. 

The speakers Prof ( Dr ) Ved Chaturvedi, DR P D RATH, and Dr. Nilesh Nolkha has immense knowledge and experience in the field of rheumatology. In this webinar they have discussed how the TNF alpha inhibitors and JAK inhibitors play a key role in altering immune responses in rheumatological diseases. 
 
TNF alpha inhibitor and JAK inhibitor drugs help in controlling inflammation in different conditions such as rheumatoid arthritis (RA), psoriatic arthritis, juvenile idiopathic arthritis, inflammatory bowel disease (Crohn's and ulcerative colitis), ankylosing spondylitis, and psoriasis. 

Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
 


See More Webinars @ Hidoc Webinars





Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Parents, teachers at Missouri school want answers after string of cancer diagnoses

2.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma

3.

Survival improved with lobectomy, segmentectomy in early non-small cell lung cancer

4.

Prostate cancer 'is not a death knell': Early detection and personalized care improve outcomes, study shows

5.

Two medications might work better for breast cancers that are resistant to one.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot